Navigation Links
Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date
Date:4/30/2009

CRANBURY, N.J., April 30 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce first quarter 2009 financial results after the regular close of markets on Thursday, May 7, 2009. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EDT.

Interested participants and investors may access the conference call at 5 p.m. EDT by dialing 877-874-1565 (U.S./Canada) or 719-325-4830 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. EDT. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 5114983.

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, an audio webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

Amicus' press releases are available at www.amicustherapeutics.com.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal stora
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
2. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
3. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
4. Amicus Therapeutics Announces Change to Board of Directors
5. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
6. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
7. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
8. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
9. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
10. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
11. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 As the R&D ... push within the industry to deliver better products, ... and pharma companies often means turning big ideas ... developed in collaboration with Sensidose AB and Recipharm, ... bring products to market sooner. The partnership resulted ...
(Date:5/21/2013)... 2013 Emerson Resources Inc. , ... Charles Signorino, the Company’s Chief Executive Officer and Chairman ... 32 years of service. As part of Emerson Resources’ ... has been named as Dr. Signorino’s successor. , ... industry, having made a significant contribution to the field ...
(Date:5/21/2013)... Md. , May 21, 2013  Synthetic Biologics, Inc. ... prevention and treatment of serious infectious diseases, announced today that ... the 2 nd Annual Marcum LLP MicroCap Conference on ... at the Grand Hyatt Hotel. Mr. Riley is ... A live webcast of Synthetic Biologics, presentation can be accessed ...
(Date:5/21/2013)... NY (PRWEB) May 21, 2013 Bed bugs ... according to My Cleaning Products, many turn to chemical-based pesticides ... of the health and environmental risks those solutions present, the ... with Bed Bug Bully instead. , According to My ... bugs as they used to be. It shared that the ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3
... ATHENS, Ohio Scientists have used new optical technologies ... principle usually would prohibit, according to a study published ... conducted experiments with high-powered lasers and quantum dots artificial ... devices for quantum communication and computing to learn ...
... MISSISSAUGA, ON, Jan. 16 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: ... operations for the,fiscal year ended November 30, 2007. ... unless otherwise noted., At November 30, 2007, ... with $30.4 million at November 30, 2006. The ...
... China, Jan. 16 /Xinhua-PRNewswire/ -- WuXi PharmaTech ... outsourcing services is,proud to announce today that ... Li is named as one of the ... Entrepreneur China edition., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ...
Cached Biology Technology:Scientists discover new method of observing interactions in nanoscale systems 2Vasogen Announces 2007 Year-End Results 2Vasogen Announces 2007 Year-End Results 3Vasogen Announces 2007 Year-End Results 4Vasogen Announces 2007 Year-End Results 5Vasogen Announces 2007 Year-End Results 6Vasogen Announces 2007 Year-End Results 7Vasogen Announces 2007 Year-End Results 8Vasogen Announces 2007 Year-End Results 9Vasogen Announces 2007 Year-End Results 10Vasogen Announces 2007 Year-End Results 11WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs 2WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs 3
(Date:5/22/2013)... in fuel cell powered buses, including a team ... electrode degradation processes and bus membrane durability. , ... degradation stressors in the operating cycle of the ... of the study, led by SFU graduate student ... study at Burnaby-based Ballard Power Systems and funded ...
(Date:5/22/2013)... major new effort to educate the public and decision ... clean water that looms ahead in the 21st century. ... current edition of Chemical & Engineering News , ... the world,s largest scientific society. , Bassam Z. Shakhashiri, ... Ph.D., explain that shortages of reliable supplies of fresh ...
(Date:5/22/2013)... to genetic engineering drastically reduces the time and ... the workhorses of biotechnology, scientists are reporting. Published ... the method paves the way for more rapid ... cleanup and other activities. , Keith Shearwin and ... of the genetic material DNA into a bacterium,s ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2
... Hypnosis can induce "synesthetic" experiences where one sense ... average brain, according to a new study in the ... the Association for Psychological Society. The findings ... do not necessarily have extra connections in their brain; ...
... infection is not a positive experience. However, by ... melanogaster with a Salmonella strain known for ... of Life Sciences at Arizona State University have ... with broad implications for understanding embryonic development, ...
... scientists say that a recent scientific study of a ... second, potentially more significant source of radon exposure for ... ore in the production arearesulted in relatively high levels ... More than half (56 percent) of the workers ...
Cached Biology News:Ben-Gurion University of the Negev researchers help find that hypnosis can induce synesthesia 2Making flies sick reveals new role for growth factors in immunity 2Making flies sick reveals new role for growth factors in immunity 3Making flies sick reveals new role for growth factors in immunity 4Major source of radon exposure overlooked at former Ohio uranium-processing plant 2Major source of radon exposure overlooked at former Ohio uranium-processing plant 3Major source of radon exposure overlooked at former Ohio uranium-processing plant 4
Request Info...
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: